Inhibition of HSP90 molecular chaperones: moving into the clinic
Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is crucial for the stability and function of many proteins essential for cell survival. Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90. Inhibition...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2013-08, Vol.14 (9), p.e358-e369 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e369 |
|---|---|
| container_issue | 9 |
| container_start_page | e358 |
| container_title | The lancet oncology |
| container_volume | 14 |
| creator | Garcia-Carbonero, Rocio, MD Carnero, Amancio, PhD Paz-Ares, Luis, Dr |
| description | Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is crucial for the stability and function of many proteins essential for cell survival. Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90. Inhibition of HSP90 causes client protein degradation via the ubiquitin–proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumour development. HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumours (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematological malignancies (eg, multiple myeloma). Here, we review the current status of HSP90 inhibitors in clinical development, including geldanamycin derivatives, resorcinol derivatives, purine analogues, and other synthetic inhibitors. We also discuss novel strategies and future perspectives on how to optimise the therapeutic potential of this exciting new class of drugs. |
| doi_str_mv | 10.1016/S1470-2045(13)70169-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751210304</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204513701694</els_id><sourcerecordid>1416042841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-47d9b2e414f728ea1c8f4548d5ec85b4a49f15a822ed0f14376fa941524dedef3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxSMEon_gI4AicSmHUI89ThwOtKgCWqkSSIWz5XUmrEvWXuykUr99nU2hUi892Xr6-XnmvaJ4A-wDMKiPrwAbVnGG8gjE-yZLbYXPiv0sYyVRqee7-4LsFQcpXTMGDTD5stjjQrU1b-R-cXrh127lRhd8Gfry_OpHy8pNGMhOg4mlXZstxeApfczqjfO_S-fHUI5rKu3gvLOvihe9GRK9vj8Pi19fv_w8O68uv3-7OPt8WVkpxFhh07UrTgjYN1yRAat6zGN2kqySKzTY9iCN4pw61gOKpu5NiyA5dtRRLw6Lo8V3G8PfidKoNy5ZGgbjKUxJQyOBAxMMn0YRaoZcIWT03SP0OkzR50VmiqtacFlnSi6UjSGlSL3eRrcx8VYD03MbeteGnqPWIPSuDT0P8vbefVptqPv_6l_8GThZAMrJ3TiKOllH3lLnItlRd8E9-cWnRw5LLWb4Q7eUHrbRiWu2mMweIHYOKO4Aq-KrTg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1412863256</pqid></control><display><type>article</type><title>Inhibition of HSP90 molecular chaperones: moving into the clinic</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central</source><creator>Garcia-Carbonero, Rocio, MD ; Carnero, Amancio, PhD ; Paz-Ares, Luis, Dr</creator><creatorcontrib>Garcia-Carbonero, Rocio, MD ; Carnero, Amancio, PhD ; Paz-Ares, Luis, Dr</creatorcontrib><description>Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is crucial for the stability and function of many proteins essential for cell survival. Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90. Inhibition of HSP90 causes client protein degradation via the ubiquitin–proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumour development. HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumours (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematological malignancies (eg, multiple myeloma). Here, we review the current status of HSP90 inhibitors in clinical development, including geldanamycin derivatives, resorcinol derivatives, purine analogues, and other synthetic inhibitors. We also discuss novel strategies and future perspectives on how to optimise the therapeutic potential of this exciting new class of drugs.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(13)70169-4</identifier><identifier>PMID: 23896275</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Androgens ; Animals ; Antineoplastic Agents - therapeutic use ; Cancer therapies ; Cytotoxicity ; Drug dosages ; Heat shock proteins ; Hematology, Oncology and Palliative Medicine ; HSP90 Heat-Shock Proteins - antagonists & inhibitors ; Humans ; Kinases ; Leukemia ; Medical prognosis ; Metabolism ; Metabolites ; Molecular Chaperones - antagonists & inhibitors ; Neoplasms - drug therapy ; Toxicity ; Tumors</subject><ispartof>The lancet oncology, 2013-08, Vol.14 (9), p.e358-e369</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-47d9b2e414f728ea1c8f4548d5ec85b4a49f15a822ed0f14376fa941524dedef3</citedby><cites>FETCH-LOGICAL-c533t-47d9b2e414f728ea1c8f4548d5ec85b4a49f15a822ed0f14376fa941524dedef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1412863256?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23896275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garcia-Carbonero, Rocio, MD</creatorcontrib><creatorcontrib>Carnero, Amancio, PhD</creatorcontrib><creatorcontrib>Paz-Ares, Luis, Dr</creatorcontrib><title>Inhibition of HSP90 molecular chaperones: moving into the clinic</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is crucial for the stability and function of many proteins essential for cell survival. Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90. Inhibition of HSP90 causes client protein degradation via the ubiquitin–proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumour development. HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumours (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematological malignancies (eg, multiple myeloma). Here, we review the current status of HSP90 inhibitors in clinical development, including geldanamycin derivatives, resorcinol derivatives, purine analogues, and other synthetic inhibitors. We also discuss novel strategies and future perspectives on how to optimise the therapeutic potential of this exciting new class of drugs.</description><subject>Androgens</subject><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Cytotoxicity</subject><subject>Drug dosages</subject><subject>Heat shock proteins</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>HSP90 Heat-Shock Proteins - antagonists & inhibitors</subject><subject>Humans</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Molecular Chaperones - antagonists & inhibitors</subject><subject>Neoplasms - drug therapy</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkU9v1DAQxSMEon_gI4AicSmHUI89ThwOtKgCWqkSSIWz5XUmrEvWXuykUr99nU2hUi892Xr6-XnmvaJ4A-wDMKiPrwAbVnGG8gjE-yZLbYXPiv0sYyVRqee7-4LsFQcpXTMGDTD5stjjQrU1b-R-cXrh127lRhd8Gfry_OpHy8pNGMhOg4mlXZstxeApfczqjfO_S-fHUI5rKu3gvLOvihe9GRK9vj8Pi19fv_w8O68uv3-7OPt8WVkpxFhh07UrTgjYN1yRAat6zGN2kqySKzTY9iCN4pw61gOKpu5NiyA5dtRRLw6Lo8V3G8PfidKoNy5ZGgbjKUxJQyOBAxMMn0YRaoZcIWT03SP0OkzR50VmiqtacFlnSi6UjSGlSL3eRrcx8VYD03MbeteGnqPWIPSuDT0P8vbefVptqPv_6l_8GThZAMrJ3TiKOllH3lLnItlRd8E9-cWnRw5LLWb4Q7eUHrbRiWu2mMweIHYOKO4Aq-KrTg</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Garcia-Carbonero, Rocio, MD</creator><creator>Carnero, Amancio, PhD</creator><creator>Paz-Ares, Luis, Dr</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130801</creationdate><title>Inhibition of HSP90 molecular chaperones: moving into the clinic</title><author>Garcia-Carbonero, Rocio, MD ; Carnero, Amancio, PhD ; Paz-Ares, Luis, Dr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-47d9b2e414f728ea1c8f4548d5ec85b4a49f15a822ed0f14376fa941524dedef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Androgens</topic><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Cytotoxicity</topic><topic>Drug dosages</topic><topic>Heat shock proteins</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>HSP90 Heat-Shock Proteins - antagonists & inhibitors</topic><topic>Humans</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Molecular Chaperones - antagonists & inhibitors</topic><topic>Neoplasms - drug therapy</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garcia-Carbonero, Rocio, MD</creatorcontrib><creatorcontrib>Carnero, Amancio, PhD</creatorcontrib><creatorcontrib>Paz-Ares, Luis, Dr</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garcia-Carbonero, Rocio, MD</au><au>Carnero, Amancio, PhD</au><au>Paz-Ares, Luis, Dr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of HSP90 molecular chaperones: moving into the clinic</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>14</volume><issue>9</issue><spage>e358</spage><epage>e369</epage><pages>e358-e369</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><abstract>Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is crucial for the stability and function of many proteins essential for cell survival. Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90. Inhibition of HSP90 causes client protein degradation via the ubiquitin–proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumour development. HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumours (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematological malignancies (eg, multiple myeloma). Here, we review the current status of HSP90 inhibitors in clinical development, including geldanamycin derivatives, resorcinol derivatives, purine analogues, and other synthetic inhibitors. We also discuss novel strategies and future perspectives on how to optimise the therapeutic potential of this exciting new class of drugs.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>23896275</pmid><doi>10.1016/S1470-2045(13)70169-4</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2013-08, Vol.14 (9), p.e358-e369 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1751210304 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central |
| subjects | Androgens Animals Antineoplastic Agents - therapeutic use Cancer therapies Cytotoxicity Drug dosages Heat shock proteins Hematology, Oncology and Palliative Medicine HSP90 Heat-Shock Proteins - antagonists & inhibitors Humans Kinases Leukemia Medical prognosis Metabolism Metabolites Molecular Chaperones - antagonists & inhibitors Neoplasms - drug therapy Toxicity Tumors |
| title | Inhibition of HSP90 molecular chaperones: moving into the clinic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T09%3A45%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20HSP90%20molecular%20chaperones:%20moving%20into%20the%20clinic&rft.jtitle=The%20lancet%20oncology&rft.au=Garcia-Carbonero,%20Rocio,%20MD&rft.date=2013-08-01&rft.volume=14&rft.issue=9&rft.spage=e358&rft.epage=e369&rft.pages=e358-e369&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(13)70169-4&rft_dat=%3Cproquest_cross%3E1416042841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1412863256&rft_id=info:pmid/23896275&rft_els_id=S1470204513701694&rfr_iscdi=true |